![]() |
产地 | 中国 |
品牌 | 爱必信(absin) |
货号 | abs813199 |
用途 | 见爱必信官网 |
英文名称 | 见爱必信官网 |
包装规格 | 5mg,5mg,5mg,5mg,10mg,10mg,10mg,10mg,25mg,25mg,25mg,25mg,50mg,50mg,50mg,50mg |
纯度 | 98%% |
CAS编号 | 572924-54-0 |
别名 | Deforolimus;AP23573;MK-8669 |
是否进口 | 否 |
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Ridaforolimus 产品别名:见爱必信官网 英文别名:Ridaforolimus 靶点:mTOR CAS:572924-54-0 纯度:98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: Ridaforolimus (Deforolimus, MK-8669)是一种选择性的mTOR抑制剂,IC50为0.2 nM;对mTOR信号通路的抑制作用及与FKBP12结合能力和Rapamycin接近。使用Deforolimus处理HT-1080细胞,抑制S6和4E-BP1磷酸化, 这种作用存在剂量依赖性,IC50分别为0.2 nM和5.6 nM, EC50分别为0.2 nM 和1.0 nM, 且导致细胞尺寸降低,G1期细胞增多,和抑制葡萄糖摄取,EC50为0.1-1 nM。Deforolimus作用于一组细胞系,具有显著抗增殖活性,EC50为0.2-2.3 nM。Deforolimus 有效且选择性抑制VEGF产量,这种作用存在剂量依赖性, EC50为~0.1 nM。 溶解性:DMSO :182 mg/mL (183.8 mM) 体外研究:
Treatment of HT-1080 cells with Deforolimus induces a dose-dependent inhibition of phosphorylation of both S6 and 4E-BP1, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, an increase in the proportion of cells in the G1 phase of the cell cycle, and inhibition of glucose uptake. Deforolimus displays significant antiproliferative activity a broad panel of cell lines with EC50 of 0.2-2.3 nM. Deforolimus potently and selectively inhibits VEGF production in a dose-dependent manner. Deforolimus treatment significantly induces growth suppression in human NSCLC cell lines with IC30 values of 2.45-8.83 nM, with the exception of H157 with IC30 of >20 nM. Deforolimus treatment (2.8-5.9 nM) significantly dephosphorylates p70S6KThr389 in A549, H1703 and H157 cells, except H1666 that may express a resistant variant of mTORC1, and causes increased phosphorylation of pAKTser473 and pAKTThr308 in A549 and H1703 cells. Deforolimus in combination with the MEK inhibitors, CI-1040 or PD0325901 exhibits dose-dependent synergism in lung cancer cell lines, which is associated with the suppression of proliferation rather than enhancement of cell death, involving the inhibition of ribosomal biogenesis by 40% within 24 hours and a decreased polysome/monosome ratio. 体内研究:Administration of Deforolimus exerts significant antitumor effects in mice bearing PC-3 (prostate), HCT-116 (colon), MCF7 (breast), PANC-1 (pancreas) or A549 (lung) xenografts in a dose-dependent manner, and inhibits mTOR signaling in in SK-LMS-1 xenograft model associated with inhibition of tumor growth.
产品信息订购:
|